论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC
Received 24 June 2016
Accepted for publication 19 September 2016
Published 31 October 2016 Volume 2016:11 Pages 5645—5669
DOI https://doi.org/10.2147/IJN.S115727
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Alexander Kharlamov
Peer reviewer comments 3
Editor who approved publication: Dr Linlin Sun
Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer
with high morbidity and mortality worldwide. Chemotherapy is recommended to
patients with intermediate or advanced stage cancer. However, the conventional
chemotherapy yields low desired response rates due to multidrug resistance,
fast clearance rate, nonspecific delivery, severe side effects, low drug
concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug
delivery system can surmount the aforementioned obstacles through enhanced
permeability and retention effect and active targeting as a novel approach of
therapeutics for HCC in recent years. The active targeting is triggered by
ligands on the delivery system, which recognize with and internalize into
hepatoma cells with high specificity and efficiency. This review focuses on the
latest targeted delivery systems for HCC and summarizes the ligands that can
enhance the capacity of active targeting, to provide some insight into future
research in nanomedicine for HCC.
Keywords: targeted therapy, hepatocellular
carcinoma, ligand, drug delivery system, nanoparticle